On water direct arylation of imidazo[1,2- a ]pyridines with aryl halides

Recent developments of imidazo[1,2-a]pyridine analogues as antituberculosis agents

Over the past 2000 years, tuberculosis (TB) has killed more people than any other infectious disease. In 2021, TB claimed 1.6 million lives worldwide, making it the second leading cause of death from an infectious disease after COVID-19. Unfortunately, TB drug discovery research was neglected in the last few decades of the twentieth century. Recently, the World Health Organization has taken the initiative to develop new TB drugs. Imidazopyridine, an important fused bicyclic 5,6 heterocycle has been recognized as a "drug prejudice" scaffold for its wide range of applications in medicinal chemistry. A few examples of imidazo[1,2-a]pyridine exhibit significant activity against multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Here, we critically review anti-TB compounds of the imidazo[1,2-a]pyridine class by discussing their development based on the structure-activity relationship, mode-of-action, and various scaffold hopping strategies over the last decade, which is identified as a renaissance era of TB drug discovery research.

Methylene-Tethered Arylsulfonation and Benzotriazolation of Aryl/Heteroaryl C-H Bonds with DMSO as a One-Carbon Surrogate

The Selectfluor-mediated approach toward the synthesis of methylene-tethered arylsulfonation and benzotriazolation of imidazopyridines has been described. The reaction involves imidazopyridine, aryl sulfinate, or benzotriazole and dimethyl sulfoxide (DMSO) in the presence of Selectfluor, where DMSO acts as a one-carbon synthon. The protocol has been extended to the methylene-tethered arylsulfonation and benzotriazolation of β-naphthols. The mechanistic insights show that the intermediate 3-((methylthio)methyl)-2-phenylimidazo[1,2-a]pyridine is generated from imidazopyridine, DMSO, and Selectfluor. The nucleophilic displacement by the aryl sulfinate salt or benzotriazole on the intermediate afforded the product.

Magnetically recoverable nickel-palladium alloy nanocatalysts for direct C-H arylation reactions

Novel magnetically recoverable nanocatalyst comprising nickel-palladium (NiPd) alloy nanoparticles (NPs) supported on reduced graphene oxide (rGO) modified with cobalt ferrite (CoFe₂O₄) NPs was fabricated for the direct C-H arylation of imidazopyridine, imidazole, indolizine and furan with aryl halides. To prepare the presented catalyst, rGO nanosheets were first modified with as-synthesized CoFe₂O₄ NPs and then the obtained CoFe₂O₄-rGO nanocomposites served as a support material for the synthesis of bimetallic NiPd alloy NPs at various compositions. The obtained CoFe₂O₄-rGO/NiPd nanocatalysts were characterized by many advanced analytical techniques including TEM, STEM-EDS, XRD, XPS, and ICP-MS. Next, to optimize the reaction conditions, CoFe₂O₄-rGO/NiPd nanocatalysts with different alloy compositions and their monometallic counterparts (CoFe₂O₄-rGO/Ni and CoFe₂O₄-rGO/Pd) were initially tested in the direct C-H arylation of imidazopyridine with bromobenzene. Among all tested nanocatalysts under the optimum reaction conditions, CoFe₂O₄-rGO/Ni₂₀Pd₈₀ showed the best catalytic activity in terms of the isolated product yields. The C-H arylation reactions were studied over a broad substrate scope (35 examples from 36 substrates) and gave the related biaryl products in good to excellent yields. Besides a broad substrate scope, the late-stage C-H arylation of zolimidine, a gastroprotective drug, was realized under the optimized reaction conditions. Moreover, the CoFe₂O₄-rGO/Ni₂₀Pd₈₀ nanocatalysts were recovered from the reaction medium using a simple magnet and reused in the C-H arylation reactions up to five consecutive runs without a significant drop in the product yield. This study shows that magnetically recoverable Pd nanoalloys are promising heterogeneous catalysts to be used in sustainable C-H functionalization reactions.

3-Aryl-substituted imidazo[1,2-a]pyridines as antituberculosis agents

Novel inhibitors are needed to tackle tuberculosis. Herein, we report the 3-aryl-substituted imidazo[1,2-a]pyridines as potent antituberculosis agents. A small library of 3-aryl-substituted imidazo[1,2-a]pyridines was synthesized using direct arylation, followed by nitro reduction and finally Pd-catalyzed C-N coupling reactions. The compounds thus obtained were evaluated against Mycobacterium tuberculosis H37Rv. Compound 26 was identified as an antituberculosis lead with a minimum inhibitory concentration of 2.3 μg/ml against M. tuberculosis H37Rv. This compound showed a selectivity index of 35. The docking of 26 in the active site of the M. tuberculosis cytochrome bc1 complex cytochrome b subunit (Mtb QcrB) revealed key π-π interactions of compound 26 with the Tyr389 and Trp312 residues of Mtb QcrB.

Diversity-Oriented Synthesis toward Aryl- and Phosphoryl-Functionalized Imidazo[1,2-a]pyridines

We report herein an efficient synthesis of diversely polysubstituted imidazo[1,2-a]pyridines, a family of aza-heterocycles endowed with numerous biological properties, through a sequence involving two consecutive palladium-catalyzed cross-coupling reactions. First, we demonstrated that a Hirao coupling occurred straightforwardly in high yields at positions 3, 5, and 6 of imidazopyridine derivatives, giving access to a wide variety of substituted phosphonates, phosphinates, and phosphine oxides. In a second step, direct CH-arylation of phosphorylimidazopyridines with aryl halides was found to be effective and fully selective, leading to 3-aryl-substituted imidazopyridines in moderate to high yields depending on steric hindrance.